Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trabectedin + indole-3-carbinol pilot study in refractory ER-positive metastatic breast cancer
2011-001288-32Phase 2Completed
- Sponsor
- Fondazione Salvatore Maugeri
- Start
- Mar 2012
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of trabectedin and indole-3-carbinol in breast cancer and estrogen receptor-positive breast cancer, sponsored by Fondazione Salvatore Maugeri. Primary endpoints: Hepatotoxicity and Safety and tolerability. Started Mar 2012; status: completed.
02
Drugs
trabectedinindole-3-carbinol
03
Conditions
breast cancerestrogen receptor-positive breast cancer
Beyond the preview
Go deeper on 2011-001288-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-001288-32.